Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Danurim is a South Korean biotechnology company specializing in the research, development, and production of functional health materials derived from black ginseng. The company employs a unique "nine-times steaming and nine-times drying" process to maximize the concentration of rare ginsenosides, such as Rg3, Rg5, and Rk1, which are known for their enhanced bioavailability and therapeutic potential. Danurim's business model encompasses the production of functional food ingredients, finished health supplements, and cosmetic raw materials. By integrating traditional herbal knowledge with modern extraction and fermentation technologies, the company aims to provide scientifically validated solutions for immune modulation, fatigue recovery, and metabolic health. Headquartered in the Geumsan region, the company operates advanced manufacturing facilities to ensure standardized quality for global markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Danurim.